MORGAN STANLEY PLC/CALL/BRISTOL-MYERS SQUIBB/80/0.1/21.03.25 | Real-time Bid/Ask 17:09:19 17/06/2024 BST | ||
| 0.022 EUR / 0.04 EUR | +34.78% |
|
| Current month | +27.78% | ||
| 1 month | -4.17% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 17/06/24 | 0.022 | -4.35% |
| 14/06/24 | 0.023 | 0.00% |
| 13/06/24 | 0.023 | -4.17% |
| 12/06/24 | 0.024 | 0.00% |
| 11/06/24 | 0.024 | +20.00% |
Delayed Quote Börse Stuttgart
Last update June 17, 2024 at 03:16 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Morgan Stanley |
| WKN | MG0XR1 |
| ISIN | DE000MG0XR17 |
| Date issued | 27/03/2024 |
| Strike | 80 $ |
| Maturity | 21/03/2025 (277 Days) |
| Parity | 10 : 1 |
| Emission price | 0.07 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.049 € |
|---|---|
| Lowest since issue | 0.016 € |
| Spread | 0.018 € |
| Spread % | 45.00% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
53.19
USD
Spread / Average Target
+29.11%
- Stock Market
- Warrants
- Warrant